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y. Abstract 
 Objectives. Psychotic symptoms frequently occur in veterans with combat-related posttraumatic stress disorder (PTSD). 
Brain-derived neurotrophic factor (BDNF) plays a major role in neurodevelopment, neuro-regeneration, neurotransmis-
sion, learning, regulation of mood and stress responses. The Met allele of the functional polymorphism, BDNF Val66Met, 
is associated with psychotic disorders. This study intended to assess whether the Met allele is overrepresented in unrelated 
Caucasian male veterans with psychotic PTSD compared to veteran controls.  Methods. The BDNF Val66Met variants were 
genotyped in 576 veterans: 206 veterans without PTSD and 370 veterans with PTSD subdivided into groups with or 
without psychotic features.  Results. Veterans with psychotic PTSD were more frequently carriers of one or two Met alleles 
of the BDNF Val66Met polymorphism than veterans with PTSD without psychotic features and veterans without PTSD. 
 Conclusions. The study shows that veterans with psychotic PTSD carried more Met alleles of the BDNF Val66Met than 
non-psychotic veterans with PTSD or veterans without PTSD. The results might add further support to the hypothesis 
that psychotic PTSD is a more severe subtype of PTSD. 
 Key words:  BDNF ,  polymorphism ,  PTSD ,  psychosis ,  veterans  Introduction 
 Psychotic symptoms, such as auditory and visual 
hallucinations, delusional thinking, paranoia and 
violent thoughts, are often present in combat veterans 
with posttraumatic stress disorder (PTSD) (Sautter 
et al. 2003; Pivac et al. 2004; Kozaric-Kovacic et al. 
2005; Kozaric-Kovacic and Pivac 2007; Braakman 
et al. 2008, 2009; Shevlin et al. 2010). PTSD with 
secondary psychotic features occurs in 30 – 40% of 
patients with combat-related PTSD (Hamner et al. 
2004; Kozaric-Kovacic and Borovecki 2005), has a 
complex clinical presentation and is often misdiag-
nosed and undertreated. Veterans with PTSD and 
comorbid psychotic disorder have a greater burden 
of disease and more severe symptoms compared to 
veterans with PTSD without psychotic features  ∗ Nela Pivac and Dragica Kozaric-Kovacic contributed equally to thi
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DOI: 10.3109/15622975.2011.582883(Hamner et al. 2004; Shevlin et al. 2010). Although 
there is no separate classifi cation of a psychotic PTSD 
subtype in the present diagnostic instruments, a recent 
meta-analysis (Braakman et al. 2008) and a review 
based on data from the National Comorbidity Survey 
(Shevlin et al. 2010) suggested that PTSD with 
secondary psychotic features might be a separate 
diagnostic entity. This suggestion is crucial for phar-
macological and psychotherapy treatment of psy-
chotic PTSD, which is different and more complex 
than the therapy of PTSD without psychotic features 
(Hamner et al. 2004; Braakman et al. 2008). 
 Brain-derived neurotrophic factor (BDNF) is a 
neurotrophin located in the hippocampus, neocor-
tex, amygdala, cerebellum and hypothalamus. BDNF 
plays a role in neuro-development, survival and s work.
tory for Molecular Neuropsychiatry, Division of Molecular Medicine, 
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y.neuronal function, synaptic plasticity, memory for-
mation and processing, learning, mood, cognition, 
molecular and behavioural responsiveness to stress 
and regulates serotonergic, glutamatergic, cholin-
ergic, and dopaminergic neurotransmission (Russo-
Neustadt 2003; Gratacos et al. 2007). Therefore, it 
is a good candidate for various psychiatric disorders 
including PTSD. The most frequently studied BDNF 
single nucleotide polymorphism (SNP) is a single 
base pair substitution G196A (Val66Met), in which 
valine (Val) is replaced with methionine (Met) at 
position 66 in the pro-BDNF sequence (Egan et al. 
2003). The Met variant of the BDNF Vall66Met 
SNP is associated with decreased activity-dependent 
BDNF secretion from the cultured hippocampal 
neurons (Egan et al. 2003). The combined Met/Met 
and Met/Val genotypes are more frequently found in 
suicide victims exposed to stressful life events in 
childhood compared to those without stressful expe-
riences (Pregelj et al. 2011), in suicide completers 
who committed suicide with violent methods com-
pared to controls (Pregelj et al. 2011) and in Alzheim-
er ' s patients with psychotic compared to those with 
non-psychotic symptoms (Pivac et al. 2011). A few 
studies evaluated the association between BDNF 
Val66Met and PTSD, with small numbers of patients, 
and found no signifi cant association (Lee et al. 2006; 
Zhang et al. 2006). A hallmark of PTSD is a reduced 
ability to suppress the traumatic fearful memories, 
and the Met allele of the BDNF Val66Met has 
been reported to be signifi cantly associated with 
a decreased activation of the ventro-medial pre-
frontal cortex, indicating impaired fear extinction 
(Frielingsdorf et al. 2010). Since Met carriers are 
overrepresented in schizophrenia and psychotic 
disorders (Gratacos et al. 2007), although see also 
(Kawashima et al. 2009), the hypothesis of this study 
was that the Met allele of the BDNF Val66Met SNP 
would be overrepresented in veterans with PTSD 
with psychotic features. As there are signifi cant 
ethnic differences in the BDNF Val66Met (Pivac 
et al. 2009), the aim of the study was to assess the 
distribution of the BDNF Val66Met variants in 
large groups of Caucasian male veterans, exposed to 
a comparable combat-related traumatic experience, 
subdivided into veterans with or without PTSD, 
with or without psychotic symptoms. 
 Methods and materials 
 Participants 
 The study included 576 male unrelated Caucasians 
from Croatia, older than 18 years (mean age 
42.3   7.1 years), who were active duty soldiers 
between 1991 – 1995 in the Croatian armed forces, with comparable traumatic combat experience 
(3.0   1.0 years). Subjects were categorized as veter-
ans with current and chronic PTSD ( N   370, 76 
with and 294 without secondary psychotic features) 
and combat exposed veterans who did not develop 
PTSD ( N   206); the groups were matched on age 
(average age 40.75   4.55 years, range 34 – 59). Vet-
erans were recruited from the University Hospital 
Dubrava, from 2003 to 2009, and 8 – 14 years elapsed 
since trauma. The majority of war veterans were 
married (69%) and 71% fi nished high schools. All 
veterans had similar social and cultural backgrounds, 
were all Croatian citizens, born and living in Croatia. 
The diagnostic procedures and inclusion and exclu-
sion criteria have been described in detail previously 
(Kozaric-Kovacic and Pivac 2007). The subjects 
were seeking treatment in our Veterans PTSD pro-
gram. The diagnosis of PTSD was made by a team 
of psychiatrists during a comprehensive screening 
evaluation, using the Structured Clinical Interview 
for DSM-IV (SCID), and based on DSM-IV crite-
ria, while psychotic and PTSD symptoms were eval-
uated using the Positive and Negative Syndrome 
Scale (PANSS) and the Clinician Administered 
PTSD Scale (CAPS), respectively. Veterans were 
subdivided into those with mild (range 46 – 65 CAPS 
scores), moderate (range 66 – 95 CAPS scores) and 
severe (range 96 – 136 CAPS scores) PTSD symp-
toms. The exclusion criteria were a history of any 
psychiatric disorders, comorbid substance abuse, 
and traumatic experience other than combat-related 
experience. Patients with comorbid depression 
(MDD) and anxious depressive disorder, which were 
secondary to the primary PTSD, were included. Psy-
chotic symptoms were more strongly associated with 
characteristics of PTSD (they were combat-related: 
scenes of war, ugly faces of dead people and slaugh-
tered, massacred, or disintegrated (dismembered) 
bodies, images of screaming soldiers or enemies try-
ing to kill them, sounds of fi re, bombing, shell and 
rocket fi re, irrational guilty feelings, etc.), than with 
characteristics of a psychosis or major depressive dis-
order with psychotic features. Psychotic symptoms 
were defi ned as evidence of hallucinations or delu-
sions during the mental status examination, with a 
score of at least 4 (moderate severity) on the positive 
items on the PANSS (delusions, conceptual disorga-
nization, hallucinatory behaviour, suspiciousness/
persecution), two negative items (emotional with-
drawal and passive/apathetic social withdrawal), 
eight items out of the general psychopathology sub-
scale (guilt feelings, depression, motor retardation, 
unusual thought content, disorientation, disturbance 
of volition, poor impulse control and active social 
avoidance), and two items on the supplementary 
subscale (anger and affective lability). The procedure 
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y.was fully explained and all veterans provided written 
informed consent to the treating psychiatrists. The 
study was approved by the Ethics committee of the 
University Hospital Dubrava and has therefore been 
performed in accordance with the ethical standards 
laid down in the 1964 Declaration of Helsinki. 
 Genetic analysis 
 Blood samples (8 ml) were drawn using plastic 
syringes with 2 ml of acid citrate dextrose antico-
agulant at 08.00 h. The DNA was isolated from 
blood using the  “ salting-out ” method (Miller et al. 
1988). The dbSNP ID for Val66Met is rs6265. 
The BDNF Val66Met polymorphism was genotyped 
in a total volume of 10  μ l, containing 30 – 100 ng 
of DNA, with the ABI Prism 7000 Sequencing 
Detection System apparatus (ABI, Foster City, USA). 
Genotyping was carried out using the Taqman-based 
allele-specifi c polymerase chain reaction assay, 
according to manufacturer ' s instructions. The prim-
ers and probes were purchased from Applied Biosys-
tems as TaqMan ® Drug Metabolism Genotyping 
Assay (assay ID: C_11592758_10). 
 Statistics 
 The results, expressed as means   standard devia-
tions or numbers and percents, were evaluated with 
Sigma Stat 3.5 (Jandell Scientifi c Corp. San Raphael, 
CA, USA). Differences in clinical scores or age 
were assessed using one-way analysis of variance 
(ANOVA) and Tukey ’ s test. The distribution of the 
BDNF genotypes and the presence of the Hardy –
 Weinberg equilibrium (HWE) were evaluated by a 
 χ 2 -test. The power of calculation ( power ), which 
should be 0.800, was evaluated using Sigma Stat 
3.5. Standardized residuals ( R ) were evaluated using 
Microsoft Excel to determine which genotype contributed to the signifi cance in the  χ 2 -test statis-
tics, and if the absolute  R value was greater than 2.00 
(http://www.acastat.com/Statbook/chisqresid.htm), 
it revealed a major infl uence on a signifi cant  χ 2 sta-
tistics. The level of signifi cance was set to  α   0.05, 
with two-tailed P values. 
 Results 
 The clinical variables for the 370 veterans with 
PTSD are presented in Table I. As expected, 
veterans with psychotic PTSD had signifi cantly 
higher total and subscale scores in the CAPS and 
PANSS than veterans with PTSD without psychotic 
symptoms (Table I). 
 The distribution of the BDNF Val66Met vari-
ants was determined in all 576 veterans (Table II). 
The genotype distribution in all PTSD veterans 
( χ 2   0.828; df   1;  P   0.363) or in veterans without 
PTSD ( χ 2   1.927; df   1;  P   0.162) was in the 
expected HWE. However, when veterans with 
PTSD were subdivided into veterans without or with 
psychotic features, there was a signifi cant deviation 
from the HWE in veterans with psychotic PTSD 
( χ 2   4.761; df   1;  P   0.029), but not in veterans 
with PTSD without psychotic symptoms ( χ 2   0.040; 
df   1;  P   0.842). 
 The frequency of the Met/Met, Met/Val and 
Val/Val genotypes ( χ  2   2.426; df   2;  P   0.297), 
Met and Val alleles ( χ 2   1.625; df   1;  P   0.202), 
or Met carriers (the combined Met/Met and Met/Val 
genotypes) versus the homozygous Val/Val geno-
type ( χ 2   1.095; df   1;  P   0.295) did not differ 
signifi cantly when all veterans with PTSD (with and 
without psychotic symptoms) were compared to 
veterans without PTSD. To evaluate the possible 
effect of the severity of PTSD symptoms, or the 
presence of the comorbid depression (MDD and 
anxious depressive disorder), regardless of the  Table I. Clinical variables in veterans with PTSD, subdivided into those with psychotic features (psychotic PTSD) and veterans with 
PTSD without psychotic features (PTSD). 
Mean   SD
PTSD with psychotic 
features ( n   76)
PTSD without psychotic 
features  ( n   294)
ANOVA; df   1,368; 
 power   1.00
 F  P 
CAPS total scores 104.1   8.0 69.0   12.1 571.051 0.001
PANSS total scores 103.9   12.8 53.7   5.6 2619.059 0.001
PANSS positive subscale scores 27.2   3.8 7.6   1.3 5441.472 0.001
PANSS negative subscale scores 13.7   3.4 8.9   2.0 242.262 0.001
PANSS general psychopathology subscale scores 52.1   6.7 30.7   4.8 1016.569 0.001
PANSS supplementary items subscale scores 10.4   1.7 6.1   3.7 96.197 0.001
Age (years) 42.03   6.83 43.37   6.44 2.681 0.109
Range (years) (29 – 60) (29 – 61)
 n is the number of subjects. CAPS, Clinician Administered PTSD Scale; PANSS, Positive and Negative Syndrome Scale;  power    power 
of calculation. 
4 N. Pivac et al.
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of the BDNF Val66Met variants, veterans were sub-
divided into those with mild, moderate and severe 
PTSD symptoms, and in those with or without com-
orbid depression. There were no signifi cant differ-
ences in the frequency of the BDNF Val66Met 
genotypes ( χ 2   5.532; df   4;  P   0.237,  power   
0.425), alleles ( χ 2   1.00; df   2;  P   0.605,  power   
 0.127), or Met carriers versus Val/Val homozygotes 
( χ 2   1.356; df   2;  P   0.508) between all veterans 
with PTSD with mild, moderate and severe PTSD 
symptoms. The frequency of the genotypes ( χ 2   
2.889; df   2;  P   0.236,  power   0.297), alleles ( χ 2   
2.557; df   1;  P   0.110,  power   0.342) or Met car-
riers versus Val/Val homozygotes ( χ 2   1.959; df   1; 
 P   0.162,  power   0.270) did not differ signifi cantly 
between all veterans with PTSD comorbid with 
MDD and anxious depressive disorder compared to 
veterans with PTSD without any comorbidities. 
 Signifi cant differences were detected in the fre-
quencies of the BDNF Val66Met variants between 
veterans with PTSD with or without psychotic 
symptoms and veterans without PTSD (Table II). 
These differences were the result of the signifi cantly 
higher frequency of the Met/Val genotype in veter-
ans with psychotic PTSD ( R   2.08) compared to 
other groups. 
 Genotype groups (Met/Met, Met/Val or Val/Val) 
did not differ signifi cantly in the mean total and 
subscale scores in the CAPS and PANSS in veterans 
with PTSD with or without psychotic symptoms 
(data available on request). 
 Discussion 
 This is the fi rst evidence of the signifi cant differences 
in the frequencies of the BDNF Val66Met variants in veterans with and without combat-related PTSD, 
further subdivided into PTSD groups with or with-
out psychotic symptoms. In line with the data show-
ing that the Met allele of the BDNF Val66Met 
polymorphism is associated with psychotic disorders 
(Gratacos et al. 2007), our results supported our 
hypothesis that veterans with psychotic PTSD are 
more frequently carriers of the Met/Val genotype, 
and the Met allele than veterans with PTSD without 
psychotic symptoms, or veterans without PTSD. In 
addition, this fi nding is consistent with our recent 
results showing that psychotic male patients with 
Alzheimer ' s disease were more frequently Met carri-
ers than carriers of the Val/Val homozygous geno-
type of the BDNF Val66Met polymorphism (Pivac 
et al. 2011). We are not aware of any direct com-
parison of the BDNF Val66Met SNP distribution 
between psychotic and non-psychotic subtypes of 
PTSD. In agreement with other studies (Lee et al. 
2006; Zhang et al. 2006), no signifi cant association 
was found in the frequency of the BDNF Val66Met 
variants between veterans with or without PTSD. 
 Veterans with psychotic PTSD have been shown 
to be non-responders to antidepressant treatment, 
however they respond well to monotherapy with 
atypical antipsychotics (Pivac et al. 2004; Kozaric-
Kovacic et al. 2005; Kozaric-Kovacic and Pivac 
2007). As shown by the signifi cantly higher total and 
subscale scores in the CAPS and PANSS, veterans 
with psychotic PTSD had more severe PTSD symp-
toms than veterans with PTSD who did not develop 
psychotic symptoms. The categorization of veterans 
into those with mild, moderate, and severe PTSD 
symptoms (according to the CAPS scores) showed 
that the Met allele status was strongly associated 
with psychotic symptoms and the more severe type  Table II. The BDNF genotype and allele count and frequencies (percentages) in male veterans with PTSD with psychotic features 
(psychotic PTSD), with PTSD without psychotic features (with PTSD) and in veterans without PTSD. 
BDNF Val66Met
Veterans with PTSD with 
psychotic features  n (%)
Veterans with PTSD without 
psychotic features  n (%)
Veterans without 
PTSD  n (%)
Met/Met genotype 1 (1.3) 11 (3.7) 3 (1.4)
Met/Val genotype 35 (46.0) 89 (30.3) 63 (30.6)
Val/Val genotype 40 (52.6) 194 (66.0) 140 (68.0)
 χ 2   10.082; df   4;  P   0.039;  power   0.718;
 R   2.08 for Met/Val genotype in veterans with psychotic PTSD
Met allele 37 (24.3) 111 (18.9) 60 (14.9)
Val allele 115 (75.7) 477 (81.1) 343 (85.1)
 χ 2   7.002; df   2;  P   0.030;  power   0.653;
 R   1.78 for Met allele in veterans with psychotic PTSD
Met carriers 36 (47.4) 100 (34.0) 66 (32.0)
Val homozygotes 40 (52.6) 194 (66.0) 140 (68.0)
 χ 2   6.023; df   2;  P   0.049;  power   0 .578;
 R   1.81 for Met carriers in veterans with psychotic PTSD
 n is the number of subjects. Frequencies (%) are shown in parentheses. BDNF: brain-derived neurotrophic factor; Met, methonine; Met 
carriers, the combined Val/Met   Met/Met genotypes; Val, valine;  power   power of calculation;  R   absolute value of the residual. 
BDNF Val66Met and psychotic PTSD        5
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is signifi cantly associated with the Met allele of 
BDNF in male subjects (Verhagen et al. 2010), our 
results showed no signifi cant association between the 
BDNF polymorphism and MDD in veterans with 
PTSD, compared to veterans with PTSD without 
any comorbidity. These data are in line with the evi-
dence that particular peripheral markers, such as 
concentrations of plasma cortisol, cerebrospinal fl uid 
corticotrophin releasing hormone, platelet serotonin, 
and activity of platelet monoamine oxidase and plasma 
dopamine beta hydroxylase, are higher in psychotic 
compared to non-psychotic PTSD (Sautter et al. 
2003; Hamner et al. 2004; Pivac et al. 2006, 2007; 
Braakman et al. 2008, 2009; Shevlin et al. 2010). We 
might speculate that early intervention for this more 
severe subtype of PTSD, complicated with psy-
chotic features, would be treatment with atypical 
antypsychotics as monotherapy, or as add-on therapy 
with antidepressants. In addition, our data might 
also suggest that therapy aimed to normalize BDNF 
function (Frielingsdorf et al. 2010), would improve 
treatment response in PTSD, especially in the psy-
chotic subtype of PTSD, which is associated with a 
higher frequency of the BDNF Met allele. 
 Although the advantage of this study was the inclu-
sion of 576 unrelated Caucasian male veterans con-
trolled for the severity of PTSD and comorbid 
depression, who were exposed to comparable trau-
matic experiences, and therefore the effect of ethnicity 
and gender on BDNF Val66Met was excluded, a pos-
sible limitation is a relatively small sample size when 
veterans were subdivided into groups with or without 
PTSD, and/or psychotic symptoms, as the power of 
calculation decreased below the desired 0.800. There-
fore, the risk of type II error might be resolved by a 
large, multicentre study comparing BDNF polymor-
phisms in psychotic versus non-psychotic PTSD. 
Despite this limitation, this study represents the fi rst 
evidence of a higher frequency of one or two Met 
alleles of the BDNF Val66Met in veterans with psy-
chotic PTSD compared to veterans with PTSD with-
out psychotic features or without PTSD. Since this 
study included only veterans with combat-related 
PTSD, the results cannot be readily generalized to 
other trauma victim populations, and therefore stud-
ies with other PTSD populations are warranted. 
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